Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

ConclusionsA small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune ‐related response evaluations may require further attention.

Source: Cancer Medicine - February 25, 2020 Category: Cancer & Oncology Authors: Patricia Martin ‐Romano, Eduardo Castanon, Samy Ammari, Stéphane Champiat, Antoine Hollebecque, Sophie Postel‐Vinay, Capucine Baldini, Andrea Varga, Jean Marie Michot, Perrine Vuagnat, Aurélien Marabelle, Jean‐Charles Soria, Charles Fe Tags: ORIGINAL RESEARCH Source Type: research